Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio— have products in the pipeline that could ...

Corticosteroids have no beneficial effect on the clinical outcome of patients with hemolysis, elevated liver enzymes and low platelets syndrome. Women who developed severe pre-eclampsia requiring ...

Hunter syndrome results from the absence of an enzyme needed to break down cellular waste. Without it, waste builds up in the body, causing progressive damage to various systems. Get top local ...

Get Instant Summarized Text (Gist) A novel enzyme, S N Ar1.3, has been developed to catalyze nucleophilic aromatic substitution reactions with high efficiency and selectivity under mild conditions ...

Nip­pon Shinyaku has paid $110 mil­lion up­front for the rights to sell two of Re­genxbio’s gene ther­a­pies for mu­copolysac­cha­ri­do­sis in the US and Asia. … ...

RegenxBio said Tuesday that Kyoto, Japan’s Nippon Shinyaku Co. Ltd. will develop and commercialize its one-time gene therapies for Hunter syndrome ... nervous system. Enzyme replacement therapy ...

With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now found a commercialization partner for both the U.S. and Asian markets.

Levels of D2S6, a biomarker of I2S activity, a key enzyme deficient in Hunter syndrome, fell by a median 86 percent among patients treated with RGX-121 at 16 weeks and approached normal levels. Hunter ...

One of the treatments, for a progressive disorder known as Hunter syndrome, could secure approval in the U.S. as soon as late this year. Should that happen, Regenxbio will retain rights to any ...

"Kraven the Hunter" partial poster featuring Aaron Taylor-Johnson. Kraven the Hunter—the Marvel box office bust starring Aaron Taylor-Johnson and Russell Crowe—debuts on digital streaming this ...